Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 325

1.

A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma.

Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert J, LaRocca R, O'Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS.

Clin Cancer Res. 2019 Jul 18. pii: clincanres.0261.2019. doi: 10.1158/1078-0432.CCR-19-0261. [Epub ahead of print]

PMID:
31320597
2.

Spectrum of Tuberculous Infection in Patients Suffering from HIV/AIDS and Its Correlation with CD-4 Counts: A Retrospective Study from Sikkim.

Kesari SP, Basnett B, Chettri A.

Indian J Otolaryngol Head Neck Surg. 2019 Jun;71(2):167-171. doi: 10.1007/s12070-016-1001-5. Epub 2016 Jun 10.

PMID:
31275824
3.

Strategy and technique of endonasal endoscopic bony decompression and selective tumor removal in symptomatic skull base meningiomas of the cavernous sinus and Meckel's cave.

Sivakumar W, Barkhoudarian G, Lobo BM, Zhang X, Zhao F, Eisenberg A, Kesari S, Krauss H, Cohan P, Griffiths C, Wollman R, Chaiken L, Kelly DF.

World Neurosurg. 2019 Jun 18. pii: S1878-8750(19)31615-8. doi: 10.1016/j.wneu.2019.06.073. [Epub ahead of print]

PMID:
31226453
4.
5.

Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives.

Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM.

Int J Nanomedicine. 2019 Mar 19;14:1937-1952. doi: 10.2147/IJN.S198353. eCollection 2019. Review.

6.

Repurposed Drugs in Treating Glioblastoma Multiforme: Clinical Trials Update.

Yadavalli S, Yenugonda VM, Kesari S.

Cancer J. 2019 Mar/Apr;25(2):139-146. doi: 10.1097/PPO.0000000000000365. No abstract available.

PMID:
30896537
7.

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors.

Piccioni DE, Achrol AS, Kiedrowski LA, Banks KC, Boucher N, Barkhoudarian G, Kelly DF, Juarez T, Lanman RB, Raymond VM, Nguyen M, Truong JD, Heng A, Gill J, Saria M, Pingle SC, Kesari S.

CNS Oncol. 2019 Mar 11. doi: 10.2217/cns-2018-0015. [Epub ahead of print]

8.

A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia.

Murphy M, Dowling A, Thien C, Priest E, Morgan Murray D, Kesari S.

CNS Oncol. 2019 Mar;8(1):CNS31. doi: 10.2217/cns-2018-0017. Epub 2019 Feb 7.

9.

An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US.

Cobbs C, McClay E, Duic JP, Nabors LB, Morgan Murray D, Kesari S.

CNS Oncol. 2019 Mar;8(1):CNS30. doi: 10.2217/cns-2018-0013. Epub 2018 Dec 14.

10.

A Binding Potency Assay for Pritumumab and Ecto-Domain Vimentin.

Babic I, Kesari S, Glassy MC.

Methods Mol Biol. 2019;1904:401-415. doi: 10.1007/978-1-4939-8958-4_19.

PMID:
30539482
11.

Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing's disease.

Minetto MA, Caresio C, Salvi M, D'Angelo V, Gorji NE, Molinari F, Arnaldi G, Kesari S, Arvat E.

J Endocrinol Invest. 2019 Jul;42(7):757-768. doi: 10.1007/s40618-018-0979-9. Epub 2018 Nov 15.

PMID:
30443856
12.

Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.

George E, Kijewski MF, Dubey S, Belanger AP, Reardon DA, Wen PY, Kesari S, Horky L, Park MA, Huang RY.

AJR Am J Roentgenol. 2018 Dec;211(6):1342-1347. doi: 10.2214/AJR.18.19988. Epub 2018 Oct 17.

PMID:
30332289
13.

Antibody drug conjugates: Progress, pitfalls, and promises.

Mukherjee A, Waters AK, Babic I, Nurmemmedov E, Glassy MC, Kesari S, Yenugonda VM.

Hum Antibodies. 2019;27(1):53-62. doi: 10.3233/HAB-180348. Review.

PMID:
30223393
14.

Unleashing endogenous TNF-alpha as a cancer immunotherapeutic.

Josephs SF, Ichim TE, Prince SM, Kesari S, Marincola FM, Escobedo AR, Jafri A.

J Transl Med. 2018 Aug 31;16(1):242. doi: 10.1186/s12967-018-1611-7. Review.

15.

Protection from chemotherapy- and antibiotic-mediated dysbiosis of the gut microbiota by a probiotic with digestive enzymes supplement.

Ichim TE, Kesari S, Shafer K.

Oncotarget. 2018 Jul 20;9(56):30919-30935. doi: 10.18632/oncotarget.25778. eCollection 2018 Jul 20.

16.

Fibroblasts as a practical alternative to mesenchymal stem cells.

Ichim TE, O'Heeron P, Kesari S.

J Transl Med. 2018 Jul 27;16(1):212. doi: 10.1186/s12967-018-1536-1. Review.

17.

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1.

18.

Cellular target engagement: a new paradigm in drug discovery.

Babic I, Kesari S, Nurmemmedov E.

Future Med Chem. 2018 Jul 1;10(14):1641-1644. doi: 10.4155/fmc-2018-0139. Epub 2018 Jun 29. No abstract available.

PMID:
29957028
19.

Profiles of brain metastases: Prioritization of therapeutic targets.

Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB.

Int J Cancer. 2018 Dec 1;143(11):3019-3026. doi: 10.1002/ijc.31624. Epub 2018 Oct 9.

20.

Rethinking medulloblastoma from a targeted therapeutics perspective.

Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR, Sanai N, Xiu J, Gatalica Z, Kim L, Kesari S, Rao G, Spetzler D, Heimberger A.

J Neurooncol. 2018 Sep;139(3):713-720. doi: 10.1007/s11060-018-2917-2. Epub 2018 Jun 5.

21.

Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.

Everson RG, Hashimoto Y, Freeman JL, Hodges TR, Huse J, Zhou S, Xiu J, Spetzler D, Sanai N, Kim L, Kesari S, Brenner A, De Monte F, Heimberger A, Raza SM.

J Neurooncol. 2018 Sep;139(2):469-478. doi: 10.1007/s11060-018-2891-8. Epub 2018 May 30.

PMID:
29846894
22.

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6. Erratum in: J Transl Med. 2018 Jun 29;16(1):179.

23.

Wnt pathway: a hallmark of drug discovery challenge.

Babic I, Yenugonda VM, Kesari S, Nurmemmedov E.

Future Med Chem. 2018 Jun 1;10(12):1399-1403. doi: 10.4155/fmc-2018-0084. Epub 2018 May 21. No abstract available.

PMID:
29779411
24.

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.

Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago OR, Hogan DJ, Gammon D, Kasahara N, Kheoh T, Jolly DJ, Gruber HE, Das A, Walbert T.

Neuro Oncol. 2018 Sep 3;20(10):1383-1392. doi: 10.1093/neuonc/noy075.

PMID:
29762717
25.

Diagnostic evaluation in steroid-induced myopathy: case report suggesting clinical utility of quantitative muscle ultrasonography.

Minetto MA, Caresio C, D'Angelo V, Lanfranco F, Ghizzoni L, Roatta S, Arvat E, Kesari S.

Endocr Res. 2018 Nov;43(4):235-245. doi: 10.1080/07435800.2018.1461904. Epub 2018 Apr 12.

PMID:
29648902
26.

Trends in spatio-temporal dynamics of visceral leishmaniasis cases in a highly-endemic focus of Bihar, India: an investigation based on GIS tools.

Mandal R, Kesari S, Kumar V, Das P.

Parasit Vectors. 2018 Apr 2;11(1):220. doi: 10.1186/s13071-018-2707-x.

27.

Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis.

Riordan NH, Morales I, Fernández G, Allen N, Fearnot NE, Leckrone ME, Markovich DJ, Mansfield D, Avila D, Patel AN, Kesari S, Paz Rodriguez J.

J Transl Med. 2018 Mar 9;16(1):57. doi: 10.1186/s12967-018-1433-7.

28.

Ependymomas overexpress chemoresistance and DNA repair-related proteins.

Ferguson SD, Zhou S, Xiu J, Hashimoto Y, Sanai N, Kim L, Kesari S, de Groot J, Spetzler D, Heimberger AB.

Oncotarget. 2017 Dec 15;9(8):7822-7831. doi: 10.18632/oncotarget.23288. eCollection 2018 Jan 30.

29.

Evaluation of Risk Factors for Laryngopharyngeal Reflux among Sikkimese Population.

Kesari SP, Chakraborty S, Sharma B.

Kathmandu Univ Med J (KUMJ). 2017 Jan.-Mar.;15(57):29-34.

PMID:
29446359
30.

Search for More Effective Chemotherapeutic Regimens for Gliomas: Challenges and Hopes.

Hu J, Kesari S.

Prog Neurol Surg. 2018;31:200-209. doi: 10.1159/000467380. Epub 2018 Jan 25. Review.

PMID:
29393187
31.

Leptomeningeal Metastases.

Graber JJ, Kesari S.

Curr Treat Options Oncol. 2018 Jan 23;19(1):3. doi: 10.1007/s11864-018-0518-0. Review.

PMID:
29362920
32.

A community affair in the tumor microenvironment.

Rodvold JJ, Kesari S, Zanetti M.

Oncotarget. 2017 Nov 21;8(63):106173-106174. doi: 10.18632/oncotarget.22586. eCollection 2017 Dec 5. No abstract available.

33.

Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.

Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R.

Cancer. 2018 Mar 15;124(6):1288-1296. doi: 10.1002/cncr.31175. Epub 2017 Dec 6.

34.

Diagnostic work-up in steroid myopathy.

Minetto MA, D'Angelo V, Arvat E, Kesari S.

Endocrine. 2018 May;60(2):219-223. doi: 10.1007/s12020-017-1472-5. Epub 2017 Nov 15. Review.

PMID:
29143179
35.

Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles.

Wang G, Benasutti H, Jones JF, Shi G, Benchimol M, Pingle S, Kesari S, Yeh Y, Hsieh LE, Liu YT, Elias A, Simberg D.

Colloids Surf B Biointerfaces. 2018 Jan 1;161:200-209. doi: 10.1016/j.colsurfb.2017.10.060. Epub 2017 Oct 23.

36.

Effect of Infla-Kine supplementation on the gene expression of inflammatory markers in peripheral mononuclear cells and on C-reactive protein in blood.

Mikirova NA, Kesari S, Ichim TE, Riordan NH.

J Transl Med. 2017 Oct 20;15(1):213. doi: 10.1186/s12967-017-1315-4.

37.

A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma.

Yenugonda V, Nomura N, Kouznetsova V, Tsigelny I, Fogal V, Nurmemmedov E, Kesari S, Babic I.

J Transl Med. 2017 Oct 18;15(1):210. doi: 10.1186/s12967-017-1312-7.

38.

Pritumumab, the first therapeutic antibody for glioma patients.

Babic I, Nurmemmedov E, Yenugonda VM, Juarez T, Nomura N, Pingle SC, Glassy MC, Kesari S.

Hum Antibodies. 2018 Feb 5;26(2):95-101. doi: 10.3233/HAB-170326. Review.

PMID:
29036806
39.

Neurological improvement of perineural and leptomeningeal spread of squamous cell carcinoma treated with intrathecal chemotherapy and systemic EGFR inhibition.

van Vugt VA, Saria MG, Javier A, Kesari N, Turpin T, Kesari S.

CNS Oncol. 2017 Oct;6(4):269-274. doi: 10.2217/cns-2017-0010. Epub 2017 Oct 6.

40.

Anxiety and Depression Associated With Burden in Caregivers of Patients With Brain Metastases.

Saria MG, Courchesne NS, Evangelista L, Carter JL, MacManus DA, Gorman MK, Nyamathi AM, Phillips LR, Piccioni DE, Kesari S, Maliski SL.

Oncol Nurs Forum. 2017 May 1;44(3):306-315. doi: 10.1188/17.ONF.306-315.

PMID:
28635984
41.

Xenon in the treatment of panic disorder: an open label study.

Dobrovolsky A, Ichim TE, Ma D, Kesari S, Bogin V.

J Transl Med. 2017 Jun 13;15(1):137. doi: 10.1186/s12967-017-1237-1.

42.

A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.

Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, Kesari S, Sarkaria JN, Zhao D, Habib AA.

Nat Neurosci. 2017 Aug;20(8):1074-1084. doi: 10.1038/nn.4584. Epub 2017 Jun 12.

43.

Cellular immunotherapy of cancer: an overview and future directions.

Tao Z, Li S, Ichim TE, Yang J, Riordan N, Yenugonda V, Babic I, Kesari S.

Immunotherapy. 2017 Jun;9(7):589-606. doi: 10.2217/imt-2016-0086. Review.

PMID:
28595516
44.

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.

Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Estrem ST, Lahn MM, Wick W.

Int J Mol Sci. 2017 May 6;18(5). pii: E995. doi: 10.3390/ijms18050995.

45.

IGF2 mRNA binding protein 3 (IMP3) promotes glioma cell migration by enhancing the translation of RELA/p65.

Bhargava S, Visvanathan A, Patil V, Kumar A, Kesari S, Das S, Hegde AS, Arivazhagan A, Santosh V, Somasundaram K.

Oncotarget. 2017 Jun 20;8(25):40469-40485. doi: 10.18632/oncotarget.17118.

46.

Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine.

Wagner SC, Ichim TE, Bogin V, Min WP, Silva F, Patel AN, Kesari S.

Oncotarget. 2017 Apr 25;8(17):28595-28613. doi: 10.18632/oncotarget.15563.

47.

Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.

Kesari S, Ram Z; EF-14 Trial Investigators.

CNS Oncol. 2017 Jul;6(3):185-193. doi: 10.2217/cns-2016-0049. Epub 2017 Apr 12.

49.

Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.

Krishnan AP, Karunamuni R, Leyden KM, Seibert TM, Delfanti RL, Kuperman JM, Bartsch H, Elbe P, Srikant A, Dale AM, Kesari S, Piccioni DE, Hattangadi-Gluth JA, Farid N, McDonald CR, White NS.

AJNR Am J Neuroradiol. 2017 May;38(5):882-889. doi: 10.3174/ajnr.A5099. Epub 2017 Mar 9.

50.

Supplemental Content

Loading ...
Support Center